Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price

Key Points

• Wedbush analysts increased their price target for Kiniksa Pharmaceuticals International from $38.00 to $44.00, indicating a potential upside of 16.13% from its current price.
• Kiniksa's stock has been rated as a "Moderate Buy" by several analysts, with a consensus price target of $45.43, despite some mixed ratings from other firms.
• The company's latest earnings report showed a revenue of $156.80 million and earnings per share of $0.23, exceeding analysts' expectations.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price objective increased by investment analysts at Wedbush from $38.00 to $44.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush's price target points to a potential upside of 16.13% from the company's current price.

A number of other equities analysts have also recently weighed in on KNSA. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a report on Thursday, September 25th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Friday, October 3rd. TD Cowen started coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a "buy" rating and a $60.00 price objective on the stock. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $45.43.

Kiniksa Pharmaceuticals International Stock Down 0.6%

Shares of NASDAQ KNSA opened at $37.89 on Monday. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $39.43. The business has a 50-day simple moving average of $35.31 and a two-hundred day simple moving average of $29.26. The company has a market cap of $2.81 billion, a P/E ratio of 947.49 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity

In other news, Director Thomas Malley sold 78,233 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the transaction, the director directly owned 12,546 shares of the company's stock, valued at approximately $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Michael R. Megna sold 17,000 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $32.35, for a total value of $549,950.00. Following the sale, the chief accounting officer owned 33,041 shares in the company, valued at $1,068,876.35. This represents a 33.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 584,471 shares of company stock valued at $19,892,061. 53.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently made changes to their positions in KNSA. Nuveen LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $16,992,000. Arrowstreet Capital Limited Partnership bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth $20,349,000. Qube Research & Technologies Ltd boosted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after acquiring an additional 651,700 shares in the last quarter. Finally, Rubric Capital Management LP boosted its holdings in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after acquiring an additional 526,567 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.